Search Results - "Fallet, V."

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets by Fallet, V., Saffroy, R., Girard, N., Mazieres, J., Lantuejoul, S., Vieira, T., Rouquette, I., Thivolet-Bejui, F., Ung, M., Poulot, V., Schlick, L., Moro-Sibilot, D., Antoine, M., Cadranel, J., Lemoine, A., Wislez, M.

“…Pulmonary sarcomatoid carcinomas (SC) are tumors characterized by poor prognosis and resistance to conventional platinum-based chemotherapy. This study sought…”
Get full text

Nivolumab-refractory patients with advanced non-small-cell lung cancer by Costantini, A., Fallet, V., Corny, J., Friard, S., Chouaid, C., Duchemann, B., Giroux-Leprieur, E., Taillade, L., Doucet, L., Brosseau, S., Wislez, M., Tredaniel, J., Cadranel, J.

“…•Hyper progressive disease is a new form of progression in patients treated with immunotherapy.•The definition of HPD is yet to be consensual.•We suggest a…”
Get full text

Head and neck (HN) primary sarcomatoid carcinoma (PSC) profile by high-throughput somatic mutation profiling by Fallet, V., Taouachi, R., Saffroy, R., Ben Lakhdar, A., Rabbe, N., André, F., Temam, S., Lemoine, A., Wislez, M.

Get full text

Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer by Pecuchet, N., Touachi, R., Ben Lakhdar, A., Fallet, V., Rabbe, N., Blons, H., Lemoine, A., Antoine, M., Tenam, S., Laurent-Puig, P., Wislez, M.

Get full text

PO-0631 INTER-FRACTION MOTION DURING 3D-CONFORMAL EXTERNAL BEAM ACCELERATED PARTIAL BREAST IRRADIATION by Levy, A, Autixier, J, Dumas, I, Boros, A, El-Khoury, C, Fallet, V, Rossier, C, Britten, A, Heymann, S, Bourgier, C

Get full text

Peri-operative management of smoking by Ruppert, A-M, Amrioui, F, Fallet, V, Cadranel, J

“…Smoking is a public health issue, especially during the perioperative period. Tobacco increases the risk of hospital mortality by 20% and major postoperative…”
Get full text

PO-1011: Impact of radiation therapy on immunotherapy efficacy in metastatic non-small cell lung cancer by Darrason, M., Rivin del Campo, E., Huguet, F., Nguenang, M., Cadranel, J., Fallet, V.

Get full text

995P Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study by Mehlman, C., Swalduz, A., Monnet, I., Morin, C., Guisier, F., Curcio, H., Du Rusquec, P., Cortot, A., Gounant, V., Abbar, B., Duchemann, B., Giroux-Leprieur, E., Pierret, T., Quilot, F.M., Cadranel, J., Fallet, V.

Get full text

34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions by Marinello, A., Duruisseaux, M., Zrafi, W.S., Dall'Olio, F.G., Massa, G., Iranzo, P., Tabbò, F., Guisier, F., Lindsay, C., Fallet, V., Audigier-Valette, C., Mezquita, L., Calles, A., Mountzios, G., Tagliamento, M., Raimbourg, J., Terrisse, S., Planchard, D., Besse, B., Aldea, M.

Get full text

1873PHead and neck (HN) primary sarcomatoid carcinoma (PSC) profile by high-throughput somatic mutation profiling by Fallet, V, Taouachi, R, Saffroy, R, Ben Lakhdar, A, Rabbe, N, André, F, Temam, S, Lemoine, A, Wislez, M

Get full text

Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions by Marinello, A., Vasseur, D., Conci, N., Lindsay, C., Metro, G., Ferrara, R., Eisert, A., Citarella, F., Fallet, V., Audugier-Valette, C., Cousin, S., Tabbò, F., Russo, A., Calles Blanco, A., Iranzo Gomez, P., Tagliamento, M., Mezquita, L., Ponce, S., Besse, B., Aldea, M.

Get full text

1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC by Marinello, A., Vasseur, D., Conci, N., Fallet, V., Audigier-Valette, C., Cousin, S., Tabbò, F., Guisier, F., Russo, A., Calles Blanco, A., Metro, G., Massa, G., Citarella, F., Eisert, A.K., Iranzo Gomez, P., Tagliamento, M., Mezquita, L., Lindsay, C., Ponce, S., Aldea, M.

Get full text

1896PDJoined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer by Pecuchet, N, Touachi, R, Ben Lakhdar, A, Fallet, V, Rabbe, N, Blons, H, Lemoine, A, Antoine, M, Tenam, S, Laurent-Puig, P, Wislez, M

Get full text

Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study by Panhaleux, Marion, Espitia, Olivier, Terrier, Benjamin, Manson, Guillaume, Maria, Alexandre, Humbert, Sébastien, Godbert, Benoît, Perrin, Julie, Achille, Aurélie, Arrondeau, Jennifer, Kostine, Marie, Fallet, Vincent, Pugnet, Grégory, Chaigne, Benjamin, Champiat, Stéphane, Laparra, Ariane, Danlos, Francois-Xavier, Launay, David, Penel, Nicolas, Lambotte, Olivier, Michot, Jean-Marie, Forestier, Alexandra

“…Cancer patients with pre-existing autoimmune disease, such as systemic sclerosis (SSc), are excluded from clinical trials, so the data on tolerability and…”
Get full text

Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts) by Perkins, G., Fabre, E., Fallet, V., Blons, H., Pecuchet, N., Gounant, V., Gibault, L., Michel-Jeljeli, E., Antoine, M., Roux, E., Wislez, M., Le Corre, D., Leroy, K., Lacave, R., Taieb, J., Cadranel, J., Laurent-Puig, P.

Get full text

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives by Giroux-Leprieur, Etienne, Fallet, Vincent, Cadranel, Jacques, Wislez, Marie

“…Around 4% of advanced non-small-cell lung cancers (NSCLCs) have an rearrangement at the time of diagnosis. This molecular feature is more frequent in young…”
Get full text

Étude SCLERONCO-1 : Étude de tolérance et de pharmacovigilance des Immune Checkpoint Inhibiteurs chez les patients ayant une SCLERodermie systémique préexistante en ONCOlogie by Panhaleux, M., Espitia, O., Terrier, B., Manson, G., Maria, A., Humbert, S., Godbert, B., Perrin, J., Achille, A., Arrondeau, J., Kostine, M., Fallet, V., Pugnet, G., Chaigne, B., Champiat, S., Lambotte, O., Michot, J.M., Forestier, A.

“…L’immunothérapie par Inhibiteurs de Checkpoint (ICP) est indiquée dans un nombre croissant de pathologies onco-hématologiques et représente un espoir…”
Get full text

Étude SCLERONCO-1 : étude de tolérance et de pharmacovigilance des Immune Checkpoint Inhibiteurs chez les patients ayant une SCLERodermie systémique préexistante en ONCOlogie by Panhaleux, M., Kostine, M., Maria, A., Arrondeau, J., Fallet, V., Achille, A., Espitia, O., Perrin, J., Godbert, B., Humbert, S., Chaigne, B., Terrier, B., Lambotte, O., Champiat, S., Michot, J.M., Forestier, A.

“…L’immunothérapie par Inhibiteurs de Checkpoint (ICP) est indiquée dans un nombre croissant de pathologies onco-hématologiques et représente un espoir…”
Get full text

Déplacements entre les fractions lors de l’irradiation partielle accélérée conformationnelle du sein by Lévy, A., Autixier, J., Dumas, I., Boros, A., El-Khoury, C., Fallet, V., Rossier, C., Britten, A., Heymann, S., Bourgier, C.

Get full text

Prise en charge du tabagisme en périoperatoire by Ruppert, A.-M., Amrioui, F., Fallet, V., Cadranel, J.

“…Le tabagisme est un problème de santé publique, en particulier chez les personnes en situation périopératoire. En effet, le tabac augmente le risque de…”
Get full text